Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet, vol.56, pp.247-58, 1999. ,
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics. févr, vol.47, issue.1, pp.75-85, 2006. ,
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry. mai, vol.9, issue.5, pp.442-73, 2004. ,
Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations, Dialogues Clin Neurosci, vol.18, issue.3, pp.323-360, 2016. ,
Pharmacogenetics and outcome with antipsychotic drugs, Dialogues Clin Neurosci. déc, vol.16, issue.4, pp.555-66, 2014. ,
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research, Mol Psychiatry. août, vol.12, issue.8, pp.707-754, 2007. ,
Pharmacogenomics: translating functional genomics into rational therapeutics, Science, vol.286, issue.5439, pp.487-91, 1999. ,
Pharmacogenomics: the inherited basis for interindividual differences in drug response, Annu Rev Genomics Hum Genet, vol.2, pp.9-39, 2001. ,
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J, vol.5, issue.1, pp.6-13, 2005. ,
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update, Pharmacopsychiatry. janv, vol.51, issue.1-02, pp.9-62, 2017. ,
DOI : 10.1055/s-0037-1600991
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0037-1600991.pdf
Psychiatric pharmacogenomic testing in clinical practice, Dialogues Clin Neurosci, vol.12, issue.1, pp.69-76, 2010. ,
Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, vol.41, issue.12, pp.913-58, 2002. ,
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update, Clin Pharmacol Ther. 20 déc, 2016. ,
De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients, Pharmacogenomics J. déc, vol.7, issue.6, pp.408-418, 2007. ,
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, Clin Pharmacol Ther, vol.72, issue.4, pp.438-52, 2002. ,
Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark, Hum Psychopharmacol Clin Exp, vol.13, issue.7, pp.509-520, 1998. ,
An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution, Hum Genet. mars, vol.95, issue.3, pp.337-378, 1995. ,
DOI : 10.1007/bf00225204
Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, pp.703-714, 2002. ,
Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, pp.300-307, 2005. ,
The star-allele nomenclature: retooling for translational genomics, Clin Pharmacol Ther. sept, vol.82, issue.3, pp.244-252, 2007. ,
DOI : 10.1038/sj.clpt.6100284
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clin Pharmacol Ther. août, vol.98, issue.2, pp.127-161, 2015. ,
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype ,
, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.234-276, 2008.
Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics, J Pers Med. 17 avr, vol.8, issue.2, 2018. ,
The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders, Drug Metab Rev. 2 déc, pp.1-41, 2018. ,
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6, Acta Psychiatr Scand. janv, vol.87, issue.1, pp.23-31, 1993. ,
DOI : 10.1111/j.1600-0447.1993.tb03325.x
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype ,
, Eur J Drug Metab Pharmacokinet. juin, vol.21, issue.2, pp.129-167, 1996.
Dopamine formation from tyramine by CYP2D6, Biochem Biophys Res Commun. 28 août, vol.249, issue.3, pp.838-881, 1998. ,
DOI : 10.1006/bbrc.1998.9232
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6 ,
, Pharmacogenetics. mars, vol.13, issue.3, pp.173-81, 2003.
Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6, Brain Res Mol Brain Res, vol.129, issue.1-2, pp.117-140, 2004. ,
Lack association between schizophrenia and the CYP2D6 gene polymorphisms, Am J Med Genet. 9 avr, vol.67, issue.2, pp.236-243, 1996. ,
DOI : 10.1002/ajmg.1320670205
Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia ,
, Psychiatr Genet, vol.8, issue.1, pp.25-33, 1998.
Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan ,
, Psychiatr Genet. sept, vol.11, issue.3, pp.153-158, 2001.
,
Interethnic variation of CYP2C19 alleles, « predicted » phenotypes and « measured » metabolic phenotypes across world populations, Pharmacogenomics J. avr, vol.16, issue.2, pp.113-136, 2016. ,
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clin Pharmacol Ther. mai, vol.93, issue.5, pp.402-410, 2013. ,
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.322-329, 2008. ,
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis, BMJ. 4 août, vol.343, p.4588, 2011. ,
Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population, Daru J Fac Pharm Tehran Univ Med Sci. 11 déc, vol.22, p.81, 2014. ,
Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metab Pers Ther, sept, vol.30, issue.3, pp.165-74, 2015. ,
Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype, J Genet. mars, vol.94, issue.1, pp.3-7, 2015. ,
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy, J Thromb Haemost JTH. août, vol.8, issue.8, pp.1685-93, 2010. ,
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther. janv, vol.79, issue.1, pp.103-116, 2006. ,
CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients, Pharmacogenomics, vol.17, issue.12, pp.1295-304, 2016. ,
High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases, Clin Pharmacol Ther. sept, vol.88, issue.3, pp.354-363, 2010. ,
CYP2D6 and the severity of suicide attempts, Pharmacogenomics. janv, vol.13, issue.2, pp.179-84, 2012. ,
Association between CYP2C19 polymorphism and depressive symptoms, Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. sept, vol.153, issue.6, pp.1160-1166, 2010. ,
DOI : 10.1002/ajmg.b.31081
Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene, Mol Psychiatry. juin, vol.19, issue.6, pp.733-774, 2014. ,
The AmpliChip CYP450 genotyping test: Integrating a new clinical tool, Mol Diagn Ther, vol.10, issue.3, pp.135-51, 2006. ,